

INTERLEAVED SEQUENCING METHOD FOR MULTIPLE TWO-DIMENSIONAL SCANNING CODES

5

Figure 1

(a) **Flowchart illustrating the process of identifying potential targets for drug repurposing.**

The flowchart starts with "Drug Repurposing" at the top, which branches into two main paths:

- Path 1 (Left):** "Target Identification" leads to "Target Validation". This path includes a box labeled "Target Identification" with sub-points: "Literature Review", "Bioassay Screening", and "Computational Modeling". Below this is a box labeled "Target Validation" with sub-points: "In Vitro Assays", "In Vivo Assays", and "Clinical Trials".
- Path 2 (Right):** "Target Identification" leads to "Target Validation". This path includes a box labeled "Target Identification" with sub-points: "Genomic Data Analysis", "Protein Structure Prediction", and "Network Analysis". Below this is a box labeled "Target Validation" with sub-points: "In Silico Modeling", "In Vitro Assays", and "In Vivo Assays".

(b) **Diagram illustrating the relationship between drug repurposing and target identification.**

This diagram shows a central box labeled "Drug Repurposing" connected by arrows to four surrounding boxes:

- "Target Identification"
- "Target Validation"
- "Drug Discovery"
- "Drug Development"

The connections are as follows:

- "Drug Repurposing" points to "Target Identification".
- "Target Identification" points to "Target Validation".
- "Target Validation" points to "Drug Discovery".
- "Drug Discovery" points to "Drug Development".

the readability of the serial number in the presence of dirt, scratches, and contamination.

2025 RELEASE UNDER E.O. 14176